Literature DB >> 27695627

Epigenetic Mechanisms: New Targets for Heart Failure Pharmacopuncture.

Yulia A Volkova1, Isaac Opoku-Asare2, Luc M Oke3, Sudhakar Pemminati4, Richard M Millis5.   

Abstract

Entities:  

Keywords:  epigenetics; histones; protein kinases; cardiac muscle

Year:  2016        PMID: 27695627      PMCID: PMC5043082          DOI: 10.3831/KPI.2016.19.019

Source DB:  PubMed          Journal:  J Pharmacopuncture        ISSN: 2093-6966


× No keyword cloud information.
Pharmacopuncture treatments are proposed for cardiovascular disease and heart failure [1]. Heart failure results from complex environment-gene interactions. β-adrenergic receptors and protein kinase A (PKA) interact with histones and related segments of deoxyribonucleic acid (DNA) at promoter regions of genes for messenger ribo nucleic acid (mRNA) transcription. This increases cardiac muscle mass and contractility in normal hearts. In heart failure, activation of β-adrenergic receptors and PKA promote pathological hypertrophy and decreased contractility. Experimental models show that prenatal exposure to hypoxia, cocaine, or nicotine increases susceptibility to heart failure when animals reach adulthood. Hypermethylation of DNA is an epigenetic mechanism associated with downregulation of the protein kinase C (PKC) gene in such models of heart failure. Downregulation of PKC is also produced by the stress-related hormone norepinephrine with upregulation of the hypoxia-inducible differentiation regulator Nix in norepinephrine-induced cardiac fibrosis [2]. Norepinephrine is also the main mediator of sympathetic neural activity. Sympathetic neural overactivity, a significant cofactor in human heart failure, is, therefore, implicated as a cofactor in this epigenetic mechanism for heart failure. Other epigenetic mechanism for cardiac hypertrophy and heart failure involve endothelin- 1 induced downregulation of the cardiac myocyte differentiation factor RE1-silencing transcription signaler (REST) and GATA zinc-finger domain-containing protein-1 (GATAD1) induced inhibition of histone deacetylase (HDAC-2) in cardiac myocytes harvested from autosomal-recessive dilated cardiac myopathy patients with heart failure [3]. In contrast, both the HDAC-2 in cardiac myocytes and the HDAC-1 in cardiac fibroblasts are upregulated in experimental animal models of congestive heart failure [4]. A prominent role for inflammation in heart failure is suggested by tumor necrosis factor (TNF-α), a proinflammatory cytokine, inducing hypermethylation of the sarcoplasmic reticulum calcium ATPase (SERCA-2A) gene in cardiac myocytes, associated with diastolic dysfunction and heart failure. An important role for epigenetic mechanisms in heart failure is also suggested by HDAC-dependent stimulation of the stress-apoptosis intracellular signaling pathway, which induces hypertrophy of both cardiac and vascular smooth muscle [5]. A treatment involving manipulation of the epigenome is shown to be effective for reversal of pathological hypertrophy of cardiac myocytes, the forerunner of heart failure. This treatment involves downregulating DNA methyltransferase (DNMT) with lithium resulting in hypomethylation of cardiac myocyte DNA, upregulation of the glycogen synthase kinase-3 beta (GS3Kβ) gene, downregulation of the cell adhesion protein β-catenin, and inhibition of the Wnt pathway for signaling of cardiac myocyte differentiation. In summary, histone and DNA acetylations/methylations appear to have multiple roles in regulating cardiomyocyte contractility and producing heart failure. Expression of epigenetic signaling molecules should, therefore, be evaluated and considered as novel molecular targets for acupuncture and pharmacopuncture for prevention and treatment of heart failure.
  5 in total

1.  Homozygosity mapping and exome sequencing reveal GATAD1 mutation in autosomal recessive dilated cardiomyopathy.

Authors:  Jeanne L Theis; Katharine M Sharpe; Martha E Matsumoto; High Seng Chai; Asha A Nair; Jason D Theis; Mariza de Andrade; Eric D Wieben; Virginia V Michels; Timothy M Olson
Journal:  Circ Cardiovasc Genet       Date:  2011-09-30

2.  The stress-related hormone norepinephrine induced upregulation of Nix, contributing to ECM protein expression.

Authors:  Weili Liu; Xinxing Wang; Jingbo Gong; Zhusong Mei; Xiujie Gao; Yun Zhao; Jing Ma; Lingjia Qian
Journal:  Cell Stress Chaperones       Date:  2014-05-07       Impact factor: 3.667

Review 3.  Alternative medicine in atrial fibrillation treatment-Yoga, acupuncture, biofeedback and more.

Authors:  Arun Kanmanthareddy; Madhu Reddy; Gopi Ponnaganti; Hari Priya Sanjani; Sandeep Koripalli; Nivedita Adabala; Avanija Buddam; Pramod Janga; Thanmay Lakkireddy; Sudharani Bommana; Ajay Vallakati; Donita Atkins; Dhanunjaya Lakkireddy
Journal:  J Thorac Dis       Date:  2015-02       Impact factor: 2.895

4.  HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation.

Authors:  Hikmet F Nural-Guvener; Luidmila Zakharova; James Nimlos; Snjezana Popovic; Diego Mastroeni; Mohamed A Gaballa
Journal:  Fibrogenesis Tissue Repair       Date:  2014-07-02

Review 5.  Dysregulation of histone acetyltransferases and deacetylases in cardiovascular diseases.

Authors:  Yonggang Wang; Xiao Miao; Yucheng Liu; Fengsheng Li; Quan Liu; Jian Sun; Lu Cai
Journal:  Oxid Med Cell Longev       Date:  2014-02-18       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.